Literature DB >> 11172790

GYKI 52466 has positive modulatory effects on AMPA receptors.

A C Arai1.   

Abstract

The 2,3-benzodiazepine derivative GYKI 52466 has been well characterized as a negative modulator of AMPA-type glutamate receptors. The present study re-examined the effects of GYKI 52466 on AMPA receptor-mediated currents in patches excised from pyramidal neurons in the hippocampal CA1 field and found that this drug has positive modulatory effects in addition to its receptor blocking action. A low concentration of GYKI 52466 (10 microM) reliably increased the steady-state current by about three-fold, while the peak current was reduced by 30% only. Higher drug concentrations produced parallel reductions in both the steady-state and peak currents. The increase in the steady-state current was not accompanied by a change in the deactivation time constant and thus, is more likely to result from a change in desensitization than a slowing of channel closing. The results indicate that GYKI 52466 modulates AMPA receptor-mediated currents in a complex manner, perhaps by acting through more than one binding site.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11172790     DOI: 10.1016/s0006-8993(00)03323-0

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  2 in total

1.  Noncompetitive antagonists induce cooperative AMPA receptor channel gating.

Authors:  Edward Y Shi; Christine L Yuan; Matthew T Sipple; Jayasri Srinivasan; Christopher P Ptak; Robert E Oswald; Linda M Nowak
Journal:  J Gen Physiol       Date:  2019-01-08       Impact factor: 4.086

2.  Seizure control by decanoic acid through direct AMPA receptor inhibition.

Authors:  Pishan Chang; Katrin Augustin; Kim Boddum; Sophie Williams; Min Sun; John A Terschak; Jörg D Hardege; Philip E Chen; Matthew C Walker; Robin S B Williams
Journal:  Brain       Date:  2015-11-25       Impact factor: 13.501

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.